Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter

Salnikov, Alexei V.; Kusumawidjaja, Grace; Rausch, Vanessa; Bruns, Helge; Groß, Wolfgang; Khamidjanov, Akmal; Ryschich, Eduard; Gebhard, Martha-Maria; Moldenhauer, Gerhard; Büchler, Markus W.; Schemmer, Peter; Herr, Ingrid

doi:10.1016/j.canlet.2008.10.015

Cited by 72 publications

(49 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the amount of CD133+/CD44+ SCLCs in metastatic liver tumors was greater than that in primary colorectal tumors, while CD133+/CD44+ SCLCs were hardly detected in the corresponding normal colorectal tissue. These data demonstrate an enrichment of CD133+CD44+ cells in metastatic cancers, which underlines that these cells may play a potential role in hepatic driving metastasis of CRC.Recently, in line with this, there have been some studies addressing CD133 and CD44 co-expression as cancer stem cell antigens in colon cancer patients [49,50]. CD44/CD133 co-expression was significantly higher in colon cancers with early liver metastases compared to those without, suggesting that CD133 and CD44 protein co-expression in colon cancer may be a potential biomarker for early liver metastasization [38].…”

supporting

confidence: 66%

“…Recently, in line with this, there have been some studies addressing CD133 and CD44 co-expression as cancer stem cell antigens in colon cancer patients [49,50]. CD44/CD133 co-expression was significantly higher in colon cancers with early liver metastases compared to those without, suggesting that CD133 and CD44 protein co-expression in colon cancer may be a potential biomarker for early liver metastasization [38].…”

Section: Metastasismentioning

confidence: 81%

See 1 more Smart Citation

Cancer Cells with Stem Cell-Like Phenotypes and Liver Metastasis from Colon Carcinoma

Bellizzi¹,

Tommasi²

2013

J Liver

View full text Add to dashboard Cite

Tumor heterogeneity contributes to the potentiality of tumors to invade and metastasize. Thus the identification of specific cells programmed to go to a specific site and establish themselves, actively proliferating and causing metastasis, could be fundamental for early diagnosis and for selective targeted therapy. Apart from gene signatures which seem to identify this tumor ability, selected cell populations with self-renewal potential have been recognized: stem cell-like cancer cells. In this paper we review recent evidence on the identification of colon cancer cells with stem cell-like properties which could have a key role in the liver metastasization. The potential clinical implication of their therapeutic eradication is also discussed. Keywords: Stem Cell-Like Cancer cells (SCLC); Colon cancer; MetastasisColorectal Cancer (CRC) is the third most common cancer in men (663,000 cases, 10.0% of the total) and the second in women (570,000 cases, 9.4% of the total) worldwide. Almost 60% of the cases occur in developed regions [1] and approximately 50% of patients develop synchronous or metachronous liver metastases within 2 years from the resection of the primary tumor [2]. Most colon cancer deaths result from the metastatic spread of tumor cells to the liver and other organs [3] and for this reason it is of great significance to identify new markers capable of discriminating earlier the potential that a primary tumor has to initiate a process of liver metastasization. The standard care in patients with operable liver-confined lesions is represented by a combination of chemotherapy and surgery [4]. However, there are still some critical issues to be solved. Firstly, surgical cures are relatively rare in this setting. Secondly, how to juxtapose chemotherapy and surgery, and the duration of chemotherapy. Finally, the possibility of pre-operative chemotherapy in the case of resectable metastases [5]. This is primarily due to the fact that current chemotherapy attacks the bulk of the cancer without affecting the chemo-resistant Stem Cell-Like Cancer cells (SCLCs). These can re-grow after treatment and, eventually, develop the changes responsible for the occurrence of drug-resistance [6][7][8] and facilitate a persistent and aggressive tumor phenotype, capable of invading other sites. In this scenario, understanding what drives metastasization to the liver and the characterization of clonal cells which selectively establish themselves in that site acquires great importance.In CRC, SCLCs are colon stem cells progenitors whose deregulated dynamics lead to the origin of a tumor [9]. At least two populations of progenitors are identified at the bottom of the normal colon Lieberkühn: true quiescent stem cells with high chemoresistance, and low proliferating potential [10]. They produce continuously the second compartment of stem cell progenitors with high mitogenic, differentiation and migratory potentials towards the top epithelium surface of the crypts. Upon migration upward through the crypt, these cells proli...

show abstract

supporting

confidence: 66%

Section: Metastasismentioning

confidence: 81%

Cancer Cells with Stem Cell-Like Phenotypes and Liver Metastasis from Colon Carcinoma

Bellizzi¹,

Tommasi²

2013

J Liver

View full text Add to dashboard Cite

show abstract

“…The capability of a minor CD133+ cell fraction to induce the identical tumor after transplantation into immune deficient mice holds true for colon carcinoma (37). Consistently, CD133 expression in high levels was shown for telomerase reverse transcriptase immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines (38). Few studies showed enhanced[CD 133] as a result of changes in receptor glycosylation (51) and alternative splicing of the extracellular domains of human CD133 which may affect presence as specific epitopes (52) Workers used A549 cells and found a 4% expression rate in mean.…”

Section: Cancer Stem Cellsmentioning

confidence: 80%

Lung Cancer Stem Cells-an Update

Srivastava¹,

Tiwari²,

Yadav³

et al. 2017

EJMR

View full text Add to dashboard Cite

Lung cancer is regarded as one of the most common cancers in the world with a worldwide occurrence of approximately 1.8 million cases and an estimated mortality of 1.6 million in 2012 alone.1 In the United States, there are approximately 2,25,000 new cases of lung cancer with over 1,60,000 deaths annually. Lung cancer is a very serious problem of the Indian subcontinent, especially in the lower socioeconomic subgroups. In India lung carcinoma is the 5th most common tumor and 2nd most common tumor in the males as per the ICMR [Indian Council Of Medical Research] registry of 2002.It accounts for 6.9% of new cancer cases detected each year.3The importance of study of stem cells and cancer stem cells lays in CSC acting as prognostic and therapeutic markers. It is a known fact that there are innate stem cells present in the lining of the bronchial epithelium, at the carina and alveolar lining which help in regeneration of lungs post injury , however there are present similar cells which post driver mutations are christened CSC and help in cancer survival, growth and chemo resistance. CSC also known as "cancer stem-like cells" (CSLCs), or "tumor-initiating cells" (TICs) are heterogeneous cell population comprising of a small subpopulation of cancer cells with the property of self-renewal and differentiation. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence, and drug resistance.Important CSC under study in lung are, CD 133, ALDH 1, CD 44,ABCG2 etc.

show abstract

“…In addition, CSCs appear dormant or with slow-cycling states (19), increase resistance to chemo-/radiotherapy (20) and furthermore, CSCs induce angiogenesis and lymphangiogenesis (21,22 recent studies support the theory that the presence of CSCs within the tumour mass correlates with poor clinical outcome, there are studies that show no such correlation (23,24). CSCs show phenotypic heterogeneity in the same type of cancer (25), but they can be isolated utilizing specific patterns of surface biomarkers, which allows their identification from non-tumorigenic cells.…”

Section: Discussionmentioning

confidence: 98%

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells

Napoletano

Bellati²,

Ruscito

et al. 2016

View full text Add to dashboard Cite

Abstract. Background: Cancer stem cells (CSCs) are tumour-initiating cells with self-renewal properties and chemo/radio-resistance. Regulatory T-cells (Tregs) influenceVulvar cancer is an uncommon gynaecological malignancy; approximately 4,850 new cases of vulvar cancer and 1,030 deaths from this disease were projected for the United States in 2014 (1). Most patients are elderly, with a peak of incidence in the eighth decade; nearly 30% are diagnosed at international Federation of Gynaecology and Obstetrics (FIGO) stage III or IV with a 5-year overall survival of 43% and 13%, respectively (2). Although representing a rare disease of elderly women with a current incidence of 2-3 per 100,000 women and a median age of 65-70 years old, vulvar cancer has shown an increasing incidence with concurrently decreasing median age of 55-60 years at onset over the past few decades (1, 3).The standard treatment of vulvar cancer includes radical surgery and adjuvant radiotherapy in selected cases. Considering the median age of these patients, clinical and pathological prognostic factors are constantly being explored in order to minimize unnecessary treatments. Furthermore, new molecules are being investigated to propose target therapies and increase patient survival.In the past decade, cancer stem cells (CSCs) have been identified as tumour-initiating cells. This subpopulation is resistant to cancer therapy such as chemo-and radiotherapies and successful treatments are dependent on the elimination of these cells (4). In addition, several reports highlight the interaction between CSCs and the immune system. 5109

show abstract

Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter

Cited by 72 publications

References 42 publications

Cancer Cells with Stem Cell-Like Phenotypes and Liver Metastasis from Colon Carcinoma

Cancer Cells with Stem Cell-Like Phenotypes and Liver Metastasis from Colon Carcinoma

Lung Cancer Stem Cells-an Update

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells

Contact Info

Product

Resources

About